Billionaire Ken Griffin More Than Doubled His Stake In This Market-Beating Growth Stock

Core Viewpoint - Ken Griffin, CEO of Citadel, significantly increased the hedge fund's stake in Eli Lilly by 184%, indicating a strong belief in the company's future performance [2]. Company Performance - Eli Lilly's revenue surged by 45% year over year in the fourth quarter, reaching $13.53 billion, showcasing exceptional growth compared to industry standards [5]. - The company's cancer drug, Verzenio, generated $1.6 billion in sales, a 36% increase year over year, while the immunosuppressant Taltz reported revenue of $952 million, up 21% [6]. Product Pipeline - Eli Lilly has a promising pipeline, particularly in the weight loss sector, with candidates performing well in trials, including mazdutide, which showed strong results in late-stage trials [7][8]. - The company is expected to introduce several new drugs in the next five years, enhancing its product portfolio [8]. Dividend Appeal - Eli Lilly has increased its dividend payouts by 200% over the past decade, with a conservative payout ratio of 44.2%, making it an attractive option for dividend-seeking investors [9].